Peer-reviewed veterinary case report
Safety of oral afoxolaner with or without milbemycin
By Drag, Marlene et al.·Published in Journal of veterinary pharmacology and therapeutics·2022·Boehringer Ingelheim Animal Health, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Safety of oral afoxolaner formulated with or without milbemycin oxime in homozygous MDR1-deficient collie dogs.
- Species:
- dog
Plain-English summary
A group of 30 adult collie dogs with a genetic condition that affects drug metabolism were given either a flea and tick treatment called afoxolaner, a heartworm medication called milbemycin oxime, or a combination of both. The dogs were monitored closely for any side effects after treatment. The results showed that afoxolaner was safe for these dogs, whether given alone or with milbemycin oxime. However, those treated only with milbemycin oxime experienced some mild and temporary neurological symptoms shortly after treatment.
People also search for: collie dog flea treatment safety · afoxolaner side effects in collies · milbemycin oxime for collies
Abstract
Afoxolaner, an insecticide and acaricide compound of the isoxazoline class, is available for dogs as an oral ectoparasiticide medicine (NexGard®) and as an oral endectoparasiticide medicine in combination with milbemycin oxime (MO), a macrocyclic lactone (NexGard® Spectra). The safety of these two compounds, alone or in combination, was investigated in homozygous MDR1-deficient collie dogs, in two studies. Overall, 30 adult collie dogs were treated once orally, 9 with a placebo, 9 with afoxolaner, 6 with MO, and 6 with a combination of afoxolaner and MO. For afoxolaner, the mean investigated dosage corresponded to 3.8 and 4.7 multiples of the maximum recommended therapeutic doses (RTD) in NexGard® and NexGard® Spectra, respectively. For MO, the mean investigated dosage corresponded to 4.7 multiples of the maximum RTD in NexGard® Spectra. Dogs were closely monitored for adverse reactions on the day of treatment and for the following two days. No significant adverse reaction was observed in any dog from the afoxolaner or the afoxolaner + MO groups; in the MO-only treated group, mild and transient neurological signs were observed during the 4-8 h post-treatment window. These studies demonstrated a high level of safety of oral afoxolaner, alone or in combination with milbemycin oxime, in homozygous MDR1-deficient dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/35536118/